NAWA - Narodowa Agencja Wymiany Akademickiej
16.12.2025 15:31:34 CET | Globenewswire | Press release
TOP200 NAWA - the Polish National Agency for Academic Exchange invites oustanding research talents to Poland
TOP200 NAWA - the Polish National Agency for Academic Exchange invites oustanding research talents to Poland
WARSAW, Poland, Dec. 16, 2025 (GLOBE NEWSWIRE) -- The TOP200 NAWA programme is a new initiative aimed at supporting transnational science cooperation and fostering excellent research in Poland.
Programme objective
The TOP200 NAWA programme aims to attract to Poland outstanding research talents from universities ranked 1 to 200 in global rankings (Shanghai Ranking, QS, THE), thereby strengthening research capacity of Polish innovation ecosystem and highlighting Poland as a destination for researchers.
Main objectives
- to provide stable employment to foreign researchers (2–4 years at Polish universities or research institutes);
- to establish predictable conditions for conducting research;
- to create possibility to set up own research teams;
- to accelerate the development of the Polish research ecosystem with viable links between science and business.
Two participation tracks
- Junior Fellow – for early-stage researchers who obtained their doctorate not earlier than 7 years before the application deadline.
- Senior Fellow – for accomplished researchers with experience in leading research teams.
Scope of support from the host institution
- Full-time employment contract for Junior Fellow/Senior Fellow.
- Access to necessary/suitable research infrastructure and administrative support.
- Assistance in adaptation and integration with the staff.
- Support in future grant applications.
Financing and the timeframe:
Call budget: PLN 17 mln from NAWA;
Submission deadline: February 27, 2026
The recommended platform for identifying a suitable academic supervisor or host institution: www.researchinpoland.org
The programme:
- is open to all fields of science,
- strengthens cooperation with the world's best research centers,
- increases the recognition of Polish science on the international stage,
- expands the capabilities of the Polish research ecosystem in terms of innovation and development,
- strengthens the infrastructure supporting the attractiveness of scientific careers,
- offers the Fellow secure place of employment and research, as well as the opportunity to take advantage of a wide range of social benefits and academic freedom,
- offers project group members and host institutions international networks, career prospects, and the opportunity to work with highly talented researchers.
More information: https://nawa.gov.pl/en/scientists/top200-nawa
The programme is a tribute to Professor Rudolf Weigl – (1883-1957) – a Pole by choice, an outstanding biologist, physician, and inventor of the world's first effective vaccine against typhus, who was nominated for the Nobel Prize several times. Born in Austria-Hungary, associated with the University of Lviv and the Jagiellonian University, he was a pioneer in the field of biology and immunology.
Source: NAWA
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/91f9d696-7ac0-4f44-ad1c-a17c44a9ffe5
CONTACT: Agata Ładykowska agata.ladykowska@nawa.gov.pl


Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
FireFly Metals Limited25.8.2026 02:49:03 CEST | Press release
Investor Presentation: Green Bay Preliminary Economic Assessment and Capital Raising
FireFly Metals Limited25.8.2026 02:44:28 CEST | Press release
Economic study demonstrates scale, grade, long life, growth potential and robust financial returns
Royal Philips24.8.2026 23:04:56 CEST | Press release
Philips prices EU green bond for EUR 650M
Lakefront Biotherapeutics24.8.2026 22:01:00 CEST | Press release
Lakefront Receives Transparency Notification from Bank of America
Lakefront Biotherapeutics24.8.2026 22:01:00 CEST | Press release
U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom